õ¿¬¹°Áú Ȱ¿ëÇØ ·ù¸¶Æ¼½º Áúȯ, ôÃß°üÀý¿° Ä¡·á ÁÖ¸ñ
±¹³»¿Ü ÇÐȸÁö¸¦ ÅëÇØ ¼ö¸¹Àº ¿¬±¸°á°ú¸¦ ¹ßÇ¥ÇÏ´Â ¿Á¤ÀûÀÎ ÀÇ»ç´Ù.
ÁÖ¿ä Áø·á ºÐ¾ß´Â °üÀý¿°(·ù¸¶Æ¼½º, °Á÷¼ºÃ´Ãß¿°, Åëdz, °ñ°üÀý¿°), ·çǪ½º ¹× Ç÷°ü¿°(·¹À̳ëÁõÈıº, º£Ã¼Æ®º´)ÀÌ´Ù. Ȳ¹é, Ȳ·Ã °°Àº ½Ä¹°ÀÇ ÃßÃâ¹°À» ÀÌ¿ëÇØ ·ù¸¶Æ¼½º Ȱ¸·¼¼Æ÷ÀÇ ±â´ÉÀ» ÁÙÀ̰ųª ¿°Áõ¹°ÁúÀ» Á¦°ÅÇÏ´Â Ä¡·á¹æ¹ýÀ» ±¹Á¦ ÇÐȸ¿¡ º¸°íÇØ ÇаèÀÇ °ü½ÉÀ» ²ø¾ú´Ù. »ý¹°ÇÐÀû Á¦Á¦, Ç¥ÀûÄ¡·áÁ¦¸¦ ÀÌ¿ëÇÑ ·ù¸¶Æ¼½º°üÀý¿°, °Á÷ôÃß¿° Ä¡·á¿¡ Àϰ¡°ßÀÌ ÀÖ´Ù.
Á¦ ¸ñ | Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024.09 | ¹ßÇ¥Áö | Korean J Intern Med. |
Á¦ ¸ñ | Korean guidelines for the management of gout. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023.09 | ¹ßÇ¥Áö | Korean J Intern Med. |
Á¦ ¸ñ | Application of Salivary Alpha-1 Antitrypsin in the Diagnosis of Rheumatoid Arthritis: A Pilot Study. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024.04 | ¹ßÇ¥Áö | Medicina |
Á¦ ¸ñ | Antinociceptive and anti-inflammatory activity of DW-1021, the ionic complex of pelubiprofen and tramadol, in rodents. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023..07 | ¹ßÇ¥Áö | Biomed Pharmacother. |
Á¦ ¸ñ | Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2021.08 | ¹ßÇ¥Áö | J Korean Med Sci. |
Á¦ ¸ñ | The bone bridge significantly affects the decrease in bone mineral density measured with quantitative computed tomography in ankylosing spondylitis. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2021.04 | ¹ßÇ¥Áö | PLoS One. |
Á¦ ¸ñ | Real-world experiences of the diagnosis process in Korean patients with ankylosing spondylitis based on a self-report questionnaire. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2021.04 | ¹ßÇ¥Áö | J Int Med Res. |
·ù¸¶Æ¼½º°üÀý¿°ÀÇ º´ÀÎ ¿¬±¸¿Í õ¿¬¹° ½Å¾à¿¡ ´ëÇÑ ¿¬±¸¸¦ ¼öÇàÇϰí ÀÖ´Ù.´Ù¾çÇÑ ·ù¸¶Æ¼½º ÁúȯÀÇ »õ·Î¿î °Ë»ç¹ý°ú Ä¡·á ¾àÁ¦ÀÇ ÀûÀÀÁõ È®´ë, º¸Çè ±Þ¿© µîÀç¿Í ±Þ¿©±âÁØ È®´ë¸¦ À§ÇØ ³ë·ÂÇϰí ÀÖ´Ù.
·ù¸¶Æ¼½º ÁúȯÀÇ Á¤È®ÇÑ Áø´Ü°ú ÃÖÀûÀÇ Ä¡·á È¿°ú´Â ¹Ù·Î °íÅë¹Þ´Â ȯÀÚ ¾È¿¡ ÀÖ´Ù´Â ¹ÏÀ½À¸·Î ȯÀÚµéÀÇ ¸»°ú Çൿ ÇѰ¡Áö¶óµµ ³õÄ¡Áö ¾Êµµ·Ï ³ë·ÂÇϰí, Áúº´ ¿ÏÄ¡¸¦ À§ÇÑ ±ä ¿©Á¤¿¡ ȯÀÚ¿Í º¸È£ÀÚ, Àǻ簡 ÇÑ °¡Á·ÀÌ µÇ¾î ³¡±îÁö ÇÔ²² µ¿ÇàÇÏ´Â »îÀ» »ì°í ½Í´Ù.
·ù¸¶Æ¼½º ÀÚ°¡¸é¿ªÁúȯÀº Àå±â°£ È£Àü°ú ¾Çȸ¦ ¹Ýº¹ÇÏ´Â ¸¸¼º ¿°ÁõÁúȯÀÌÁö¸¸, ÃÖ±Ù¿¡´Â ¿ÏÄ¡¿¡ µµÀüÇÏ´Â Çõ½ÅÀûÀÎ Ä¡·áÁ¦µéÀÌ ¸¹ÀÌ °³¹ßÀÌ µÇ¾î ¾ú½À´Ï´Ù.Á¶±â Áø´Ü°ú Á¶±â Ä¡·áÀ» ÅëÇØ¼ ¹«¼¿î Áúº´ÀÇ °íÅë¿¡¼ ¹þ¾î³ª ¾ó¸¶µçÁö Áñ°Ì°í ÇູÇÑ »îÀ» »ì ¼ö ÀÖÀ¸´Ï, º´¿¡ °É·È´Ù°í Àý¸ÁÇϰųª Æ÷±âÇÏÁö ¸¶½Ã°í Àû±ØÀûÀ¸·Î Ä¡·áÇÏ½Ã±æ ²À ´çºÎµå¸³´Ï´Ù.
°æÈñ´ëÇб³º´¿øÀº ȯÀÚ Áß½ÉÀÇ ÀÇ·á ¼ºñ½º¸¦ Á¦°øÇϸç, ±¹³» ÀÇ·á°è¸¦ ¼±µµÇÏ´Â »ó±ÞÁ¾ÇÕº´¿øÀÔ´Ï´Ù. ÃֽŠÀÇ·á ±â¼ú°ú Àåºñ¸¦ Ȱ¿ëÇÏ¿© ȯÀڵ鿡°Ô ÃÖ»óÀÇ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ÁßÁõÁúȯ Ä¡·á ¹× ¿¬±¸¿¡ °Á¡À» º¸À̸ç, ´ÙÇÐÁ¦ ÇùÁø ½Ã½ºÅÛÀ» ÅëÇØ ȯÀÚÀÇ °Ç°À» ÃÖ¿ì¼±À¸·Î »ý°¢ÇÕ´Ï´Ù. °æÈñ´ëÇб³º´¿øÀº ȯÀÚµéÀÇ ½Å·Ú¿Í ¸¸Á·µµ¸¦ ³ôÀÌ´Â µ¥ ÁÖ·ÂÇϸç, Áö¼ÓÀûÀ¸·Î ÀÇ·á ǰÁú Çâ»ó°ú ¿¬±¸ °³¹ß¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã µ¿´ë¹®±¸ °æÈñ´ë·Î 23 °æÈñ´ëÇб³º´¿ø